Impact of clinical pharmacists intervention on management of hyperglycemia in pregnancy in Jordan.
Razan Adnan BattaViolet KasabriAmal AkourDana HyassatAbla Albsoul-YounesPublished in: International journal of clinical pharmacy (2017)
Background and objective Hyperglycemia in pregnancy is a risk factor for cardiovascular disease and postpartum (PP) diabetes. This study aimed to assess the impact of the clinical pharmacist-assisted program (CPAP) of optimizing drug therapy and intensive education on main management outcome measures of patient knowledge about diabetes, Quality of life (QoL) as measured by SF-36 including maternal complications, fasting plasma glucose (FPG) control, and HbA1c. Method This is a randomized controlled study. Pregnant (20-28 weeks) patients with hyperglycemia received CPAP (n = 51) as compared with conventional management (n = 34). Patients were then followed up for 6 weeks pp. Results A significant change was shown in the intervention group for diabetes knowledge (3.47% vs. control 2.03%, P < 0.05) and three aspects of health-related QoL. The need for caesarian delivery (58.8% vs. control 35.3%) and severe episodes of hypoglycemia (0% vs. control 8.8%) were significantly (P < 0.05) reduced in the intervention group. Six weeks PP reduction in HbA1c values was greater in the intervention group (- 0.54% vs. control - 0.08%, P = 0.04) with more FPG-controlled patients during pregnancy (94% vs. control 64.7%). Conclusion Clinical pharmacist assisted services in the management of pregnancy hyperglycemia fundamentally and significantly improve knowledge and disease control.
Keyphrases
- cardiovascular disease
- healthcare
- type diabetes
- randomized controlled trial
- newly diagnosed
- ejection fraction
- pregnant women
- preterm birth
- pregnancy outcomes
- obstructive sleep apnea
- glycemic control
- emergency department
- case report
- physical activity
- mental health
- stem cells
- blood pressure
- adipose tissue
- primary care
- coronary artery disease
- body mass index
- gestational age
- patient reported outcomes
- bone marrow
- diabetic rats
- drug induced
- health insurance
- birth weight
- adverse drug